The stock of Arcutis Biotherapeutics Inc (ARQT) has seen a 12.15% increase in the past week, with a 30.87% gain in the past month, and a -8.02% decrease in the past quarter. The volatility ratio for the week is 9.82%, and the volatility levels for the past 30 days are at 8.43% for ARQT. The simple moving average for the last 20 days is 19.51% for ARQT stock, with a simple moving average of 62.12% for the last 200 days.
Is It Worth Investing in Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Right Now?
The 36-month beta value for ARQT is also noteworthy at 1.18. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ARQT is 99.22M, and at present, short sellers hold a 26.22% of that float. The average trading volume of ARQT on July 09, 2024 was 2.98M shares.
ARQT) stock’s latest price update
The stock price of Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has plunged by -0.57 when compared to previous closing price of 10.49, but the company has seen a 12.15% gain in its stock price over the last five trading sessions. investorplace.com reported 2024-07-06 that Savvy investors are discovering rewarding opportunities in some of the best stocks under $10 a share. Years ago, I found Advanced Micro Devices (NASDAQ: AMD ) at $10 a share and watched it rocket above $200 on the artificial intelligence (AI) boom.
Analysts’ Opinion of ARQT
Many brokerage firms have already submitted their reports for ARQT stocks, with Mizuho repeating the rating for ARQT by listing it as a “Buy.” The predicted price for ARQT in the upcoming period, according to Mizuho is $8 based on the research report published on January 03, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see ARQT reach a price target of $4, previously predicting the price at $57. The rating they have provided for ARQT stocks is “Neutral” according to the report published on October 26th, 2023.
Goldman gave a rating of “Neutral” to ARQT, setting the target price at $6 in the report published on October 13th of the previous year.
ARQT Trading at 20.78% from the 50-Day Moving Average
After a stumble in the market that brought ARQT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.80% of loss for the given period.
Volatility was left at 8.43%, however, over the last 30 days, the volatility rate increased by 9.82%, as shares surge +37.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.20% upper at present.
During the last 5 trading sessions, ARQT rose by +12.15%, which changed the moving average for the period of 200-days by +59.72% in comparison to the 20-day moving average, which settled at $8.87. In addition, Arcutis Biotherapeutics Inc saw 222.91% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARQT starting from Welgus Howard G., who sale 10,000 shares at the price of $9.31 back on Jul 01 ’24. After this action, Welgus Howard G. now owns 180,339 shares of Arcutis Biotherapeutics Inc, valued at $93,141 using the latest closing price.
Welgus Howard G., the Director of Arcutis Biotherapeutics Inc, sale 10,000 shares at $8.01 during a trade that took place back on Jun 04 ’24, which means that Welgus Howard G. is holding 170,200 shares at $80,092 based on the most recent closing price.
Stock Fundamentals for ARQT
Current profitability levels for the company are sitting at:
- -1.85 for the present operating margin
- 0.93 for the gross margin
The net margin for Arcutis Biotherapeutics Inc stands at -2.04. The total capital return value is set at -0.46. Equity return is now at value -119.24, with -50.68 for asset returns.
Based on Arcutis Biotherapeutics Inc (ARQT), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at -0.97. The debt to equity ratio resting at 0.9. The interest coverage ratio of the stock is -6.52.
Currently, EBITDA for the company is -239.22 million with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 11.5. The receivables turnover for the company is 2.86for trailing twelve months and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.89.
Conclusion
In summary, Arcutis Biotherapeutics Inc (ARQT) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
